Clinical research platform uMotif has raised £20 million from a New York investment firm.
The London company’s patient-first software platform is available on any device and designed to service pharmaceutical, BioTech, MedTech and contract research organisation clients including AstraZeneca.
Deployed in more than 30 countries globally, it claims to deliver high rates of data capture, patient retention, data quality and delivery speed – ultimately helping achieve faster, better trials.
The investment comes from a fund managed by Athyrium Capital Management, which is based in New York. Existing investors AlbionVC and DNV, which led a Series A investment round in 2020, also joined.
It will support further international expansion and continued development of patent-protected solutions for pain, clinical outcome and symptom tracking.
Having entered the US in 2021, and with support of a US-based healthcare investor, uMotif’s North American team will significantly grow – including in sales, marketing and service delivery.
“We are delighted to welcome Athyrium to support our journey to be the most patient-centric platform for research,” said Steve Rosenberg, CEO.
“I truly believe that clinical research must put patients first, delivering more engaging research studies. With this investment from Athyrium I’m excited to grow our global capabilities to better serve our sponsors, partners and – most importantly – the patients we help take part in research.”
Mark Kavulich, partner at Athyrium said: “Over recent years we have seen how the global eClinical market is significantly growing and quickly changing. uMotif’s approach to engaging patients in research is truly differentiated, patent-protected and is built on technology ready to scale.
“We’re excited to be joining the uMotif journey and supporting significant scale up in the coming years.”